上海宝济药业股份有限公司（宝济药业-B，股票代码：02659）于2026年6月1日发布2026年5月的证券变动月报表。报告显示，截至5月31日，公司各类已发行股份总体数量保持不变，未进行任何新增发行、购回或注销行为，股本结构稳定。
根据公告披露，公司本月末普通股H股（于香港联交所上市）维持154,327,250股，面值均为每股人民币0.2，总计股本为30,865,450元人民币；内资股数量为171,654,215股，面值均为每股人民币0.2，总计股本为34,330,843元人民币。公司本月底法定/注册股本总额为65,196,293元人民币。报告期内未显示任何期权、认股权证或可换股票据的变动，也未发生购回或授出期权等情况。
公告由公司执行董事刘彦君签署，并重申公司遵守香港联交所《上市规则》及其他相关法律规定。根据公告信息显示，公司目前股本维持不变，符合相关监管要求。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.